Young David 4

What Happened

• David Young, President of Research & Development and a director at Processa Pharmaceuticals (PCSA), acquired 1,810 shares on 2026-03-31.
• The shares were purchased at $2.54 per share for a total transaction value of $4,588. This was a purchase (a bullish signal in that it is an insider buy rather than a sale), not a sale or option exercise.

Key Details

• Transaction date: 2026-03-31; Filing date (Form 4): 2026-04-01 (accession 0000897069-26-000756). Filing appears to be within the normal 2-business-day window; no late-filing flag noted.
• Transaction type/code: Purchase (P) — described as an open-market or private purchase.
• Price and size: 1,810 shares at $2.54 per share; total reported value $4,588.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes/plans: No 10b5-1 plan, tax withholding, or other footnotes were indicated in the provided data.

Context

• Insider purchases are often watched by retail investors as a potential sign of confidence, though small-dollar buys (like this ~$4.6k purchase) can be routine and don’t on their own indicate a major change in insider conviction.
• No derivatives, exercises, gifts, or immediate sales were reported in this transaction — just a straightforward purchase.